Electromed initiated with a Buy at B. Riley

B. Riley analyst Kyle Bauser initiated coverage of Electromed (ELMD) with a Buy rating and $38 price target Electromed is a profitable, growing medical device company that manufactures and sells high-frequency chest wall oscillation airway clearance products for patients with chronic respiratory conditions, the analyst tells investors in a research note. The firm believes the company can reach $1.00 per share of earnings by fiscal 2026 and reach 20% operating margins over time. Electromed is also an attractive takeout target for a larger medical technology strategy looking to leverage the pulmonologist call point, contends B. Riley.